Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.
In particular, the HGB-205 trial demonstrated the long-term benefits of lentiviral gene therapy for β-hemoglobinopathies, such as sickle ... healthy stem cells. Lentiviral Vectors (LV): A type ...
the treatment is hailed as a revolutionary method for targeting the root genetic causes of diseases ranging from sickle cell to cancer. Some gene therapy treatments use modified adeno-associated ...
the treatment is hailed as a revolutionary method for targeting the root genetic causes of diseases ranging from sickle cell to cancer. Some gene therapy treatments use modified adeno-associated ...
In December 2023, the FDA approved the first Crispr-based therapy for sickle cell disease ... the family of adeno-associated virus (AAV) vectors already provides the ability to achieve in vivo ...
That’s the view of analysts at Jefferies, who suggest it could “re-ignite concerns over the use of lentiviral vectors and the ... 2 trial in patients with sickle cell disease (SCD) – another ...
including a study of CRISPR Therapeutics and Vertex Pharma’s CRISPR ex vivo drug for blood disorders beta thalassaemia and sickle cell disease. Allergan and Editas say they will test AGN-151587 ...
The original Crispr technology involved making cuts in DNA to disable genes, which has proven effective for certain conditions like sickle cell disease ... the use of adeno-associated virus (AAV) ...
“Currently, we are developing a pipeline of products to transfer to our Brazilian partners, starting with those used to treat haematological cancers, but then expanding to CAR-T therapies that target ...
A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely ...
Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback